Inhaler for Asthma

Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterizing by variable and recurring symptoms, reversible airflow obstruction, and bronchospasm. Therefore symptoms include episodes of wheezing, coughing, chest tightness; and shortness of breath. These may occur a few times a day or a few times per week. Depending on the person; they may become worse at night or with exercise.
Asthma is thought to cause by a combination of genetic and environmental factors. So environmental factors include exposure to air pollution and allergens. Meanwhile, in other potential triggers include medications such as aspirin and beta blockers. Diagnosis is usually based on the pattern of symptoms; response to therapy over time, and spirometry.
Hence, Asthma is classified according to the frequency of symptoms, forced expiratory volume in one second (FEV1); and peak expiratory flow rate. Meanwhile, it may classify as atopic or non-atopic; where atopy refers to a predisposition toward developing a type 1 hypersensitivity reaction.

Inhaler for Asthma and COPD

So the first generic version of the widely used Advair Diskus inhaler for asthma and chronic obstructive pulmonary disease (COPD) has won U.S. Food and Drug Administration approval. This approval “is part of our longstanding commitment to advance access to lower cost; high-quality generic alternatives,” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research.
But in people living with asthma and COPD know too well the critical importance of having access to the treatment they need to feel better. Today’s approval will bring more competition to the market; which will ultimately benefit the patients who rely on this drug,” Woodcock said Wednesday in an agency news release. The new inhaler, from drug maker Mylan; contains fluticasone propionate and salmeterol inhalation powder.

So it’s approved for twice-daily treatment of asthma in patients aged 4 years and older. In COPD cases, it’s approved for maintenance treatment of airflow obstruction and reducing exacerbations. Asthma is a chronic lung disease that inflames and narrows the airways. More than 26 million people in the US are known to have it; so it including about 7 million children, the FDA noted.

Progressive Lung Disease

Therefore COPD is a progressive lung disease that affects breathing and often worsens over time. As a result, symptoms can include coughing that produces large amounts of mucus, wheezing, shortness of breath, and chest tightness. Therefore the inhaler comes in three strengths: fluticasone propionate 100 mcg/salmeterol 50 mcg; fluticasone propionate 250 mcg/salmeterol 50 mcg; and fluticasone propionate 500 mcg/salmeterol 50 mcg.
Most importantly in asthma patients, subsequently the most common side effects of this combination treatment are upper respiratory tract infection or inflammation; as a result, swelling in the back of the throat; hoarse voice or trouble speaking; oral thrush also called candidiasis; bronchitis; cough; headaches; nausea and vomiting. Consequently, in COPD patients, the most common side effects are pneumonia; oral candidiasis; throat irritation; hoarse voice or trouble speaking; viral respiratory infections; headaches; and musculoskeletal pain.